Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study

Overview

Journal Integr Cancer Ther

Publisher Sage Publications

Specialties Oncology
Pharmacology

Date 2021 Nov 16

PMID 34781754

Citations 3

Authors

Chao Hou

Die Yang

Yusen Zhang

Yifei Li

Zhengfei He

Xiaojun Dai

Qingyun Lu

Shanshan Wang

Xiaochun Zhang

Yanqing Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the therapeutic effect of Traditional Chinese Medicine (TCM), specifically Fuzheng Qingdu (FZQD) therapy, on the survival time of metastatic GC patients.

Patients And Methods: Databases of medical records of 6 hospitals showed that 432 patients with stage IV GC were enrolled from March 1, 2012 to October 31, 2020. Propensity score matching (PSM) was used to reduce the bias caused by confounding factors in the comparison between the TCM and the non-TCM users. We used a Cox multivariate regression model to compare the hazard ratio (HR) value for mortality risk, and Kaplan-Meier survival curve for the survival time of GC patients.

Results: The same number of subjects from the non-TCM group were matched with 122 TCM-treated patients after PSM to evaluate their overall survival (OS) and progression-free survival (PFS). Median time of OS of TCM and non-TCM users were 16.53 and 9.10 months, respectively. TCM and non-TCM groups demonstrated a 1-year survival rate of 68.5% and 34.5%, 2-year survival rate of 28.6% and 3.5%, and 3-year survival rate of 17.8% and 0.0%, respectively. A statistical difference exists in OS between the 2 groups (χ = 33.39 and < .0001). The PFS of TCM users was also longer than that of non-TCM users (χ = 4.95 and = 0.026). Notably, Chinese herbal decoction, Shenmai and compound Kushen injections were commonly used for FZQD therapy.

Conclusion: This propensity-matched study showed that FZQD therapy could improve the survival of metastatic GC patients.

Citing Articles

Brucea javanica Seed Oil Emulsion and Shengmai Injections Improve Peripheral Microcirculation in Treatment of Gastric Cancer.

Quan L, Niu W, Yang F, Zhang Y, Ding R, He Z Chin J Integr Med. 2024; .

PMID: 39225883 DOI: 10.1007/s11655-024-4103-z.

Effects of Traditional Chinese Medicine "Fuzheng Qingdu Decoction" on Autonomic Function and Cancer-Related Symptoms in Patients with Advanced Gastric Cancer undergoing Chemotherapy: A Controlled Trial.

Yuan C, Wu S, Wu Y, Tian C, Wang Z, Zhang X Integr Cancer Ther. 2024; 23:15347354241229414.

PMID: 38323452 PMC: 10851715. DOI: 10.1177/15347354241229414.

Real-World Evidence of Traditional Chinese Medicine (TCM) Treatment on Cancer: A Literature-Based Review.

Peng L, Zhang K, Li Y, Chen L, Gao H, Chen H Evid Based Complement Alternat Med. 2022; 2022:7770380.

PMID: 35815277 PMC: 9259235. DOI: 10.1155/2022/7770380.

References

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

Wang K, Chen Y, Lu A, Du G, Qin X, Guan D . A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC. J Ethnopharmacol. 2021; 274:114043. DOI: 10.1016/j.jep.2021.114043. View

Liu S, Lu C, Cheng H, Xi H, Cui J, Li J . Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chin Med J (Engl). 2015; 128(16):2194-201. PMC: 4717974. DOI: 10.4103/0366-6999.162497. View

He M, Wang F, Jin Y, Yuan S, Ren C, Luo H . Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci. 2018; 109(11):3575-3582. PMC: 6215885. DOI: 10.1111/cas.13813. View

Zhao X, Dai X, Wang S, Yang T, Yan Y, Zhu G . Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size. Evid Based Complement Alternat Med. 2018; 2018:4369027. PMC: 6083736. DOI: 10.1155/2018/4369027. View

Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y . Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003; 94(11):1015-20. PMC: 11160149. DOI: 10.1111/j.1349-7006.2003.tb01394.x. View

Liu X, Li M, Wang X, Dang Z, Yu L, Wang X . Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine. 2019; 62:152930. DOI: 10.1016/j.phymed.2019.152930. View

Lan H, An P, Liu Q, Chen Y, Yu Y, Luan X . Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. J Ethnopharmacol. 2021; 274:114073. DOI: 10.1016/j.jep.2021.114073. View

Thrift A, El-Serag H . Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2019; 18(3):534-542. PMC: 8859863. DOI: 10.1016/j.cgh.2019.07.045. View

10.

Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S . Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2015; 19(1):234-44. PMC: 4688303. DOI: 10.1007/s10120-015-0457-4. View

11.

Wang F, Shen L, Li J, Zhou Z, Liang H, Zhang X . The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019; 39(1):10. PMC: 6423835. DOI: 10.1186/s40880-019-0349-9. View

12.

He R, Ou S, Chen S, Ding S . Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect. Med Sci Monit. 2020; 26:e918520. PMC: 6977710. DOI: 10.12659/MSM.918520. View

13.

Cheng L, Liu W, Zhong C, Ni P, Ni S, Wang Q . Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy. J Ethnopharmacol. 2021; 270:113770. DOI: 10.1016/j.jep.2020.113770. View

14.

Shih W, Yang P, Shen Y, Yang Y, Wu C . Traditional Chinese Medicine Enhances Survival in Patients with Gastric Cancer after Surgery and Adjuvant Chemotherapy in Taiwan: A Nationwide Matched Cohort Study. Evid Based Complement Alternat Med. 2021; 2021:7584631. PMC: 7889357. DOI: 10.1155/2021/7584631. View

15.

Jung Y, Jerng U, Lee S . A systematic review of anticancer effects of radix astragali. Chin J Integr Med. 2015; 22(3):225-36. DOI: 10.1007/s11655-015-2324-x. View

16.

Zhang X, Lv S, Zhang W, Jia Q, Wang L, Ding Y . Shenmai injection improves doxorubicin cardiotoxicity via miR-30a/Beclin 1. Biomed Pharmacother. 2021; 139:111582. DOI: 10.1016/j.biopha.2021.111582. View

17.

Wu J, Liu S, Zhu J, Zhang D, Wang K . Efficacy of Oil Emulsion Injection Combined with the Chemotherapy for Treating Gastric Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2018; 2018:6350782. PMC: 5954888. DOI: 10.1155/2018/6350782. View

18.

Xu C, Guo X, Zhou C, Zhang H . Brucea javanica oil emulsion injection (BJOEI) as an adjunctive therapy for patients with advanced colorectal carcinoma: A protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(27):e21155. PMC: 7337478. DOI: 10.1097/MD.0000000000021155. View

19.

Liu X, Xiu L, Jiao J, Zhao J, Zhao Y, Lu Y . Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis. J Integr Med. 2017; 15(6):469-475. DOI: 10.1016/S2095-4964(17)60377-7. View

20.

Luo H, Xu R, Wang F, Qiu M, Li Y, Li F . Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010; 56(2):94-100. DOI: 10.1159/000305256. View